1 Crohn’s Disease: Executive Summary
1.1 Summary of changes
1.2 Steady growth is expected for the CD market from 2022-32
1.3 Novel MOAs will provide market shifts throughout the forecast period
1.4 Lack of tools to properly treat patients with CD is a clear unmet need within the market
1.5 Pipeline Drugs
1.6 What Do Physicians Think?
2 Introduction
2.1 Catalyst
2.2 Related reports
2.3 Upcoming reports
3 Disease Overview
3.1 Etiology and pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 CD Classification
4 Epidemiology
4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 8MM forecast methodology
4.4.1 Sources
4.4.2 Forecast assumptions and methods
4.4.3 Forecast assumptions and methods: diagnosed incident cases of CD
4.4.4 Forecast assumptions and methods: diagnosed prevalent cases of CD
4.4.5 Forecast assumptions and methods: diagnosed prevalent cases of CD by severity, diagnosed prevalent cases of fistulizing CD by severity, and diagnosed prevalent cases of CD in remission by severity
4.5 Epidemiological forecast for Crohn’s disease (2022-32)
4.5.1 Diagnosed incident cases of CD
4.5.2 Age-specific diagnosed incident cases of CD
4.5.3 Sex-specific diagnosed incident cases of CD
4.5.4 Diagnosed prevalent cases of CD
4.5.5 Age-specific diagnosed prevalent cases of CD
4.5.6 Sex-specific diagnosed prevalent cases of CD
4.5.7 Diagnosed prevalent cases of CD by severity
4.5.8 Diagnosed prevalent cases of fistulizing CD by severity
4.5.9 Diagnosed prevalent cases of CD in remission by severity
4.6 Discussion
4.6.1 Epidemiological forecast insight
4.6.2 COVID-19 impact
4.6.3 Limitations of the analysis
4.6.4 Strengths of the analysis
5 Disease Management
5.1 Diagnosis and treatment overview
5.2 KOL insights on disease management
6 Current Treatment Options
6.1 Overview
7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Improved Drug Efficacy, Clinical Response, and Sustained Remission
7.3 Biomarkers to Predict Responsiveness to Therapy and Prognosis
7.4 Improved Medical Management of Perianal Fistulas
7.5 Clinical Data to Determine the Most Efficacious Therapy
8 R&D Strategies
8.1 Overview
8.1.1 Novel MOAs
8.1.2 Biomarkers
8.2 Clinical Trials Design
8.2.1 Patient inclusion criteria
8.2.2 Endpoints
9 Pipeline Assessment
9.1 Overview
9.2 Promising drugs in clinical development
10 Pipeline Valuation Analysis
10.1 Overview
10.2 Competitive assessment
11 Current and Future Players
11.1 Overview
11.2 Deal-making trends
12 Market Outlook
12.1 Global Markets
12.1.1 Forecast
12.1.2 Drivers and barriers - global issues
12.2 US
12.2.1 Forecast
12.2.2 Key events
12.2.3 Drivers and barriers
12.3 5EU
12.3.1 Forecast
12.3.2 Key events
12.3.3 Drivers and barriers
12.4 Japan
12.4.1 Forecast
12.4.2 Key Events
12.4.3 Drivers and barriers
12.5 Canada
12.5.1 Forecast
12.5.2 Key events
12.5.3 Drivers and barriers
13 Appendix
13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
13.3.1 Forecasting Methodology
13.4 Primary Research - KOLs Interviewed for This Report
13.4.1 KOLs
13.5 Primary Research - Prescriber Survey
13.6 About the Authors
13.6.1 Analyst
13.6.2 Managing Analyst
13.6.3 Epidemiologist
13.6.4 Reviewers
13.6.5 Global Director of Therapy Analysis and Epidemiology
- About the Analyst
- Contact the Publisher
List of Tables
Table 1: CD: Key metrics in the 8MM
Table 2: Summary of changes to CD Eight-Market Drug Forecast and Analysis to 2032
Table 3: Crohn’s disease severities
Table 4: Risk factors and comorbidities for CD
Table 5: Treatment guidelines for CD
Table 6: Top 10 deals by value, 2018-2024
Table 7: CD market - global drivers and barriers, 2022-32
Table 8: Key events impacting sales for CD in the US, 2022-32
Table 9: CD market - drivers and barriers in the US, 2022-32
Table 10: Key events impacting sales for CD in the 5EU, 2022-32
Table 11: CD market - drivers and barriers in the 5EU, 2022-32
Table 12: Key events impacting sales for CD in Japan, 2022-32
Table 13: CD market - drivers and barriers in Japan, 2022-32
Table 14: Key events impacting sales for CD in Canada, 2022-32
Table 15: CD market - drivers and barriers in Canada, 2022-32
Table 16: High-prescribing physicians (non-KOLs) surveyed, by country
List of Figures
Figure 1: Global sales forecast by country for CD in 2022 and 2032
Figure 2: Analysis of the company portfolio gap in CD during the forecast period
Figure 3: Competitive assessment of the late-stage biologics benchmarked against Humira
Figure 4: Competitive assessment of the late-stage small molecules benchmarked against Rinvoq
Figure 5: Pathophysiology of Crohn’s disease
Figure 6: 8MM, diagnosed incidence of CD, men and women, cases per 100,000 population, all ages, 2022
Figure 7: 8MM, diagnosed prevalence of CD, men and women, %, all ages, 2022
Figure 8: 8MM, sources used and not used to forecast the diagnosed incident cases of CD
Figure 9: 8MM, sources used and not used to forecast the diagnosed prevalent cases of CD
Figure 10: 8MM, diagnosed incident cases of CD, N, both sexes, all ages, 2022
Figure 11: 8MM, diagnosed incident cases of CD by age, N, both sexes, 2022
Figure 12: 8MM, diagnosed incident cases of CD by sex, N, all ages, 2022
Figure 13: 8MM, diagnosed prevalent cases of CD, N, both sexes, all ages, 2022
Figure 14: 8MM, diagnosed prevalent cases of CD by age, N, both sexes, 2022
Figure 15: 8MM, diagnosed prevalent cases of CD by sex, N, all ages, 2022
Figure 16: 8MM, diagnosed prevalent cases of CD by severity, N, both sexes, ages < 18 years, 2022
Figure 17: 8MM, diagnosed prevalent cases of CD by severity, N, both sexes, ages =18 years, 2022
Figure 18: 8MM, diagnosed prevalent cases of fistulizing CD by severity, N, both sexes, ages < 18 years, 2022
Figure 19: 8MM, diagnosed prevalent cases of fistulizing CD by severity, N, both sexes, ages =18 years, 2022
Figure 20: 8MM, diagnosed prevalent cases of CD in remission by severity, N, both sexes, ages < 18 years, 2022
Figure 21: 8MM, diagnosed prevalent cases of CD in remission by severity, N, both sexes, ages =18 years, 2022
Figure 22: Unmet needs and opportunities in CD
Figure 23: Overview of the development pipeline in CD
Figure 24: Key late-stage trials for the promising pipeline agents that the analyst expects to be licensed for CD in the 8MM during the forecast period
Figure 25: Competitive assessment of the late-stage biologics benchmarked against Humira
Figure 26: Competitive assessment of the late-stage small molecules benchmarked against Rinvoq
Figure 27: Analysis of the company portfolio gap in CD during the forecast period
Figure 28: Global (8MM) sales forecast by country for CD in 2022 and 2032
Figure 29: Sales forecast by class for CD in the US in 2022 and 2032
Figure 30: Sales forecast by class for CD in the 5EU in 2022 and 2032
Figure 31: Sales forecast by class for CD in Japan in 2022 and 2032
Figure 32: Sales forecast by class for CD in Canada in 2022 and 2032
